[1] ROMANO S, BUCCHERI S, MEHRAN R, et al.Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease[J]. Expert Opin Drug Saf, 2018, 17(10): 1041-1052. [2] FARKOUH A, RIEDL T, GOTTARDI R, et al.Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature[J]. Adv Ther, 2020, 37(2): 644-655. [3] WAINER Z, CARCEL C, HICKEY M, et al.Sex and gender in health research: updating policy to reflect evidence[J]. Med J Australia, 2020, 212(2): 57. [4] HARRISON-WOOLRYCH M.Medicines for women[M]. Springer International Publishing, 2015. [5] ISLAM MM, IQBAL U, WALTHER BA, et al.Gender-based personalized pharmacotherapy: a systematic review[J]. Arch Gynecol Obstet, 2017, 295(6): 1305-1317. [6] ROSANO G MC, LEWIS B, AGEWALL S, et al.Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1[J]. Eur Heart J, 2015, 36(40): 2677-2680. [7] WEBER MA, SCHIFFRIN EL, WHITE W B, et al.Clinical practice guidelines for the management of hypertension in the community[J]. The Journal of Clinical Hypertension, 2014, 16(1): 14-26. [8] ARPON D R, GANDHI M K, MARTIN JH.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug[J]. Brit J Clin Pharmaco, 2014, 78(2): 274-281. [9] KALIBALA J, PECHERE-BERTSCHI A, DESMEULES J.Gender differences in crdiovascular pharmacotherapy-the example of hypertension: a mini review[J]. Front Pharmacol, 2020, 11: 564. [10] SABBATINI AR, KARARIGAS G.Estrogen-related mechanisms in sex differences of hypertension and target organ damage[J]. Biol Sex Differ, 2020, 11(1): 31. [11] LI L.Analysis of 112 cases of adverse drug reactions induced by antihypertensive drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(8): 485-486. [12] UENO K, SATO H.Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs[J]. Hypertens Res, 2012, 35(3): 245-250. [13] GUO C, PEI Q I, TAN H, et al.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients[J].Biomedical Reports, 2015, 3(2): 195-200. [14] DENTON K M, HILLIARD L M, Tare M.Sex-related differences in hypertension: seek and ye shall find[J]. Hypertension, 2013, 62(4): 674-677. [15] RYDBERG D M, MEJYR S, LOIKAS D, et al.Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs[J]. Eur J Clin Pharmacol, 2018, 74(9): 1165-1173. [16] HU S, CHENG J, WEINSTOCK J, et al.A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension[J].J Hum Hypertens, 2018, 32(11): 781-788. [17] FAULKNER JL, BELIN DCE.Female Sex, a major risk factor for salt-sensitive hypertension[J]. Curr Hypertens Rep, 2020, 22(12): 99. [18] ASMAR R, OPARIL S.Comparison of the antihypertensive efficacy of irbesartan//HCTZ and valsartan//HCTZ combination therapy: impact of age and gender[J]. Clin Exp Hypertens, 2010, 32(8): 499-503. [19] WANG H, CHEN H.Gender difference in the response to valsartan/amlodipine single-pill combination in essential hypertension (China Status II): an observational study[J]. J Renin-Angio-Aldo S, 2016, 17(2): 1878746874. [20] DEBORDE T, AMAR L, BOBRIE G, et al.Sex differences in antihypertensive treatment in France among 17856 patients in a tertiary hypertension unit[J]. J Hypertens, 2018, 36(4): 939-946. [21] BENJAMIN EJ, BLAHA MJ, CHIUVE SE, et al.Heart disease and stroke statistics-2017 update: a report from the American Heart Association[J]. Circulation,2017, 135(10): e146-e603. [22] FRANKENSTEIN L, CLARK AL, RIBEIRO JP.Influence of sex on treatment and outcome in chronic heart failure[J]. Cardiovasc Ther, 2012, 30(3): 182-192. [23] HAN LL, BAI XJ.Heart failure in women[J]. Chin J Geriatr Heart Brain Vessel Dis(中华老年心脑血管病杂志), 2016, 18(8): 883-886. [24] KOTECHA D, MANZANO L, KRUM H, et al.Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis[J]. BMJ, 2016, 353: i1855. [25] NARULA HS, CARLSON HE.Gynaecomastia--pathophysiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2014, 10(11): 684-698. [26] WEI Y, OU SP, WU LL, et al.Retrospective analysis of the monitoring results of digoxin blood concentration and its influencing factors[J]. Journal of Modern Medicine & Health(现代医药卫生), 2021, 37(2): 276-278. [27] MEHTA LS, BECKIE TM, DEVON H A, et al.Acute myocardial infarction in Women[J]. Circulation, 2016, 133(9): 916-947. [28] FARKOUH A, RIEDL T, GOTTARDI R, et al.Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature[J]. Adv Ther, 2020, 37(2): 644-655. [29] PLAKOGIANNIS R, ARIF SA.Women versus men: is there equal benefit and safety from statins?[J]. Curr Atheroscler Rep, 2016, 18(2): 6. [30] Women's Health Group, Chinese society of cardiology.Chinese expert advisory on female antithrombotic therapy[J]. Chinese Journal of Cardiology(中华心血管病杂志), 2020, 48(6): 443-449. [31] KO D, RAHMAN F, SCHNABEL RB, et al.Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis[J]. Nat Rev Cardiol, 2016, 13(6): 321-332. [32] KO D, RAHMAN F, MARTINS M AP, et al.Atrial fibrillation in women: treatment[J]. Nat Rev Cardiol, 2017, 14(2): 113-124. [33] ZELNIKER TA, ARDISSINO M, ANDREOTTI F, et al.Comparison of the efficacy and safety outcomes of edoxaban in 8040 women vrsus 13 065 men with atrial fibrillation in the ENGAGE AF-TIMI 48 trial[J]. Circulation, 2021, 143(7): 673-684. [34] PALAMANER S S G, MENTIAS A, INAMPUDI C, et al. Sex‐specific associations of oral anticoagulant use and cardiovascular outcomes in patients with atrial fibrillation[J]. J Am Heart Assoc, 2017, 6(8): e006381. [35] LINDE C, BONGIORNI M G, BIRGERSDOTTER-GREEN U, et al.Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society[J]. Europace, 2018, 20(10): 1565. [36] ZHONG B, WANG Y, ZHANG G, et al.Environmental iodine content,female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid[J]. Cardiology, 2016, 134(3): 366-371. |